A new treatment to boost fertility | Pharmaceutical | The Pharmaletter

Female fertility specialist Oxolife has announced positive Phase II clinical data for its OXO-001 fertility pill.

OXO-001 is a non-hormonal drug designed to improve embryo implantation in women undergoing treatments such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).

Agnes Arbat, the company’s CEO, said: “Most IVF or ICSI cycles still end in failure, often because a viable embryo does not implant.”

This article is available to registered users. To continue reading, sign up for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in pharma and biotech for one week. If you are already a registered user, please log in. If your trial has ended, you can subscribe here.

Sign into your account

Try before you buy

Free

Access to the 7-day trial

Try it for free

All the news that is shaking up the pharmaceutical and biotechnology industry
Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life sciences journalists.
Receive The Pharma Letter daily newsletter for free for life.

Become a subscriber

£820

Or £77 per month

Subscribe now

Unlimited access to cutting-edge news, commentary and analysis in the pharmaceutical and biotechnology sector.
Clinical trial news, conferences, mergers and acquisitions, licensing, financing, regulation, patents and legal aspects, executive appointments, business strategy and financial results.
Daily roundup of key events in the pharmaceutical and biotechnology sector.
In-depth monthly briefings on board appointments and M&A news.
Choose between a cost-effective annual plan or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on the performance of people and products. It is one of the key pieces of information to keep me informed

President, Sanofi Aventis UK